Inside NEU: The ASX pharma star with a long runway for growth

Jump back to 2021 and Neuren Pharmaceuticals Ltd (ASX: NEU) share price consistently traded around $1.50 and occasionally breached $2. Within three years it would hit a high of $25 a share. NEU received FDA approval for a drug called Trofenetide, a drug which treats a rare syndrome called Rett Syndrome. With a drug on the shelves in the US, NEU now has the cashflows to self-fund the next leg of growth. In this Australian Investors Podcast episode, your host Mitchell Sneddon sits down with Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX: NEU) to discuss: – The impact of trofinetide on Rett syndrome patients and families – How Neuren partnered to distribute trofinetide in the US – The lifecycle of drug development – Neuren’s ability to self-fund future R&D and the opportunity with NNZ-2591 – Company culture and separating share price from business performance If you love learning about ASX biotechs and healthcare investing, subscribe to the Australian Investors Podcast on Apple, Spotify, or YouTube! Topics Covered – Trofinetide’s life-changing impact on Rett syndrome patients – The commercialisation and distribution partnership in the US – Stages of drug development explained – Neuren’s strategy to self-fund future growth – The culture at Neuren Pharmaceuticals – The potential of NNZ-2591 and timelines for progress – Why investors should separate business performance from share price movement Resources for This Episode – Neuren Pharmaceuticals – Trail to a Texas Trial – Visit TermPlus to learn more Rask Resources 🔗 Explore all Rask services 📋 Get Financial Planning 📈 Start investing with Rask 📜 Access Show Notes ❓ Ask a question – just select the Investors Podcast 📲 Follow us on social media: – Instagram: @rask.invest – TikTok: @rask.invest DISCLAIMER This podcast contains general financial information only. That means the information does not take into account your objectives, financial situation, or needs. You should consider if the information is appropriate for your situation before acting on it. If you’re unsure, consult a licensed financial planner. The Rask Group is NOT a qualified tax accountant, financial adviser, or tax professional. You can access The Rask Group’s Financial Services Guide (FSG) here. Learn more about your ad choices. Visit megaphone.fm/adchoices